31737-09-4

Basic information

• Product Name: 6-CHLORO-1-METHYLURACIL
• Synonyms: 6-CHLORO-1-METHYLURACIL;6-Chloro-1-methylpyrimidine-2,4(1H,3H)-dione
• CAS NO: 31737-09-4
• Molecular Formula: C₅H₅ClN₂O₂
• Molecular Weight: 160.56
• Mol File: 31737-09-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 186 °C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.51g/cm³
• Refractive Index: 1.58
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 8.36±0.40(Predicted)
• CAS DataBase Reference: 6-CHLORO-1-METHYLURACIL(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-1-METHYLURACIL(31737-09-4)
• EPA Substance Registry System: 6-CHLORO-1-METHYLURACIL(31737-09-4)

Safety Data

• Hazardous Substances Data: 31737-09-4(Hazardous Substances Data)

Usage

Uses

6-Chloro-1-methyluracil was used to develop new syntheses of alloxazine 5-oxides and fervenulin 4-oxides by the nitrative cyclization.

InChI:InChI=1/C5H5ClN2O2/c1-8-3(6)2-4(9)7-5(8)10/h2H,1H3,(H,7,9,10)

Upstream product

• 1188497-82-6 C₆H₅ClN₂O₃ 
• 89-25-8 edaravone 
• 4270-27-3 6-chlorouracil 
• 74-88-4 methyl iodide 

Downstream Products

• 7269-04-7 6-(N-phenylamino)-1-methyluracil 
• 42542-57-4 1-methyl-6-phenyl-2,4(1H,3H)-pyrimidinedione 
• 1797409-07-4 6-(dimethylamino)-1-methylpyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

A novel synthesis of fused uracils: Indenopyrimidopyridazines, pyrimidopyridazines, and pyrazolopyrimidines for antimicrobial and antitumor evalution

A variety of different compounds of fused uracils were prepared simply by the heating of 6-hydrazinyl-1-methyl-, 6-hydrazinyl-1-propyl-, or 6-hydrazinyl-1,3-dipropyluracil under reflux with ninhydrin, isatin, benzylidene malononitrile, benzylylidene ethyl cyanoacetate, benzil, and phenacyl bromide derivatives. The newly synthesized compounds were completely screened for antimicrobial and antitumor activity.

Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is considered to be a promising therapeutic target for several inflammation-associated diseases. Herein, we describe the discovery of a series of pyrimidone derivatives as Lp-PLA2 inhibitors. Systematic structural modifications led to the identification of several pyrimidone compounds with promising in vitro inhibitory potency and pharmacokinetic properties. Compound 14c, selected for in vivo evaluation, demonstrated decent pharmacokinetic profiles and robust inhibitory potency against Lp-PLA2 in Sprague-Dawley (SD) rats. Furthermore, 14c significantly inhibited retinal thickening in STZ-induced diabetic SD rats as a model of diabetic macular edema (DME) after oral dosing for 4 weeks. Taken together, these results suggested that 14c can serve as a valuable lead in the search for new Lp-PLA2 inhibitors for prevention and/or treatment of DME.

A mild and efficient method for the deformylation of 5-formyl uracils and synthesis of 4,4￠-methylidenebis(1-phenyl-3-methyl-5-pyrazolone)

6-Substituted 5-formyl uracils undergo an interesting reaction with 1-phenyl-3-methyl-5-pyrazolone in the presence of base catalyst to afford deformylated uracils and 4,4￠-methylidenebis(1-phenyl-3-methyl-5- pyrazolone) in excellent yields. Georg Thieme V